These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 9629873)

  • 21. Clinical practice guidelines on antiemetics in oncology.
    Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Parameters that influence the outcome of nausea and emesis in cisplatin based chemotherapy.
    Tsavaris N; Kosmas C; Mylonakis N; Bacoyiannis C; Kalergis G; Vadiaka M; Boulamatsis D; Iakovidis V; Kosmidis P
    Anticancer Res; 2000; 20(6C):4777-83. PubMed ID: 11205218
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Options in the treatment of chemotherapy-induced emesis.
    Pendergrass KB
    Cancer Pract; 1998; 6(5):276-81. PubMed ID: 9767346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population.
    Lindley CM; Bernard S; Fields SM
    J Clin Oncol; 1989 Aug; 7(8):1142-9. PubMed ID: 2787840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
    Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support.
    Paul B; Trovato JA; Thompson J; Badros AZ; Goloubeva O
    J Oncol Pharm Pract; 2010 Mar; 16(1):45-51. PubMed ID: 19525301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy.
    Molassiotis A; Nguyen AM; Rittenberg CN; Makalinao A; Carides A
    Future Oncol; 2013 Oct; 9(10):1443-50. PubMed ID: 23987791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rolapitant: a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2016 Mar; 12(6):871-9. PubMed ID: 26806790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study.
    Molassiotis A; Aapro M; Dicato M; Gascon P; Novoa SA; Isambert N; Burke TA; Gu A; Roila F
    J Pain Symptom Manage; 2014 May; 47(5):839-848.e4. PubMed ID: 24075401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiemetic research: future directions.
    Olver I; Molassiotis A; Aapro M; Herrstedt J; Grunberg S; Morrow G
    Support Care Cancer; 2011 Mar; 19 Suppl 1():S49-55. PubMed ID: 21063733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of chemotherapy-induced nausea and vomiting.
    Tortorice PV; O'Connell MB
    Pharmacotherapy; 1990; 10(2):129-45. PubMed ID: 2190193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
    Holdsworth MT; Raisch DW; Winter SS; Chavez CM
    Support Care Cancer; 1998 Mar; 6(2):132-8. PubMed ID: 9540172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methodology of antiemetic trials: a review.
    Tonato M; Roila F; Del Favero A
    Ann Oncol; 1991 Feb; 2(2):107-14. PubMed ID: 2054311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methodology in anti-emetic trials.
    Olver IN
    Oncology; 1992; 49(4):269-72. PubMed ID: 1522983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors and antiemetic management of chemotherapy-induced nausea and vomiting.
    Goodman M
    Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):20-32. PubMed ID: 9282378
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New directions in managing chemotherapy-related emesis.
    Krasnow SH
    Oncology (Williston Park); 1991 Sep; 5(9 Suppl):19-24. PubMed ID: 1836346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.